Work

Discovery and Characterization of Zilurgisertib, a Potent and Selective Inhibitor of Activin Receptor-like Kinase-2 (ALK2) for the Treatment of Fibrodysplasia Ossificans Progressiva

Year: 2025

Type: article

Source: ACS Medicinal Chemistry Letters

DOI: 10.1021/acsmedchemlett.5c00516

Authors: Thomas Ullrich, Sabine Guth, Luca Arista, Sven Weiler, Nikolaus Stiefl, Sylvie Teixeira-Fouchard, Carien Dekker, Alexandra Hinniger, Victoria Head, Michaela Kneissel, Ina Kramer

Institution: Novartis (Switzerland)

Language: English

Topic: Heterotopic Ossification and Related Conditions

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415737827

FWCI: 0.64

Cites: 16

Cited by: 1

Related to: